2023-508824-36-00Active, not recruitingPhase 2
HOPE in Diabetic Kidney Disease (HyperpOlarised PyruvatE in Diabetic Kidney Disease)
QUANTITATIVE RENAL HYPERPOLARIZED [1-13C]PYRUVATE PERFUSION AND METABOLIC IMAGING IN DIABETIC KIDNEY DISEASE
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Feb 2025
Brief summary (registry, in English)
We hypothesise that classification of diabetic kidney disease progression is possible with the application of quantitative hyperpolarised [1-13C]pyruvate MRI.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- First submitted
- 6 Dec 2023
- Start date
- 24 Sept 2024
- Lead sponsor
- Aarhus Universitet
- Diseases
- Chronic kidney disease
- EU CT number
- 2023-508824-36-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 27
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindications for MRI: Significant cardiac disease, Obstructive lung disease, pacemaker, neurostimulator, cholera implant, metal foreign bodies, claustrophobia, largest circumference including arms > 160 cm.
- Competing systemic diseases
- Pyruvate Allergy
Other
- Stents or other devices implanted close to the kidneys that may cause imaging artifacts
Who the study is looking for
- All participants: Aged 18 – 85 years and pre-menopausal women must be confirmed non-pregnant.
- Type 1 Diabetes Mellitus with diabetic kidney disease: eGFR > 15ml/min and eGFR=< 60 ml/min and urine albumin-creatinine ratio > 100 mg/g)
- Type 1 diabetes mellitus without diabetic kidney disease: eGFR > 60 ml/min and no albuminuria (urine albumin-creatinine ratio < 30 mg/g) and No signs of proliferative retinopathy or macular edema.
- Control Subjects must have eGFR>60
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarhus Universitet | Aarhus N | Denmark | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.